About AltruBio
AltruBio is a Healthcare company based in San Francisco (United States) by Ron Rh Lin. It operates as a drugs for immune-mediated inflammation and cancer are developed. AltruBio has raised $339.6 million across 7 funding rounds from investors including Blackstone, RA Capital and BVF Partners. The company has 10 employees. Its chief executive is Judy Chou. Its focus areas include Life Sciences, Oncology, Drugs and Diversified.
Company details
Developer of drugs for immune-mediated inflammation and cancer therapies. Its product AbGn-168H Neihulizumab is a humanized therapeutic antibody that induces apoptosis of late-stage activated T cells. This novel activated-T cell apoptosis-inducing antibody effectively eliminates chronic pathogenic T cells while fully maintaining host defense. It helps in the treatment of psoriatic arthritis, ulcerative colitis, and many more. The lead product AbGn-107 targets novel tumor-associated antigens on the surface of certain gastrointestinal cancers including the stomach, biliary system, pancreas, intestine, and rectum. The antibody can be internalized once it binds to cancer cells where the concentrated toxin efficiently kills the cancer cells. Other products include AbGn-268 Leiolizumab helps in treating inflammation diseases, AbGn-207 GI tumors.
- Headquarters San Francisco, United States
- Employees 10
- Founders Ron Rh Lin
- SectorsHealthcare
- Website altrubio.com/altrubio/en
- Social LinkedIn X
- Total Equity Funding$339.6M (USD)
in 7 rounds
- Latest Funding Round$225M (USD), Series B
May 2024
- InvestorsBlackstone
& 6 more
- Employee Count10
Funding Insights of AltruBio
AltruBio has successfully raised a total of $339.6M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $225 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $339.6M
- Total Rounds 7
- Last Round Series B — $225M
- First Round $6.15M
(Jul 2008)
- Investors Count 7
All 7 funding rounds of AltruBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $225M | Series B | – | BVF Partners | |
| Apr 2021 | $63M | Series A | – | aMoon | |
| Aug 2014 | $16M | Series A | – | – | – |
| Jun 2013 | $9.6M | Series A | – | – | – |
| Jun 2012 | $16.85M | Series A | – | – | – |
| Apr 2010 | $3M | Series A | – | – | – |
| Jul 2008 | $6.15M | Series A | – | – | – |
7 investors in total: 7 institutional.
Investors in AltruBio
AltruBio has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Blackstone, RA Capital and BVF Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US private equity investments are managed by BVF Partners. | – | bvflp.com | San Francisco, United States | |
- | – | soleuscapital.com | - | |
Venture capital investments in healthcare are focused on by aMoon. | – | amoon.fund | - | |
Diversified investment management is provided across multiple asset classes. | 1985 | blackstone.com | New York, United States | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Manages diversified investment portfolios across various asset classes. | 1997 | cormorant.com | Boston, United States | |
Investment firm managing opportunistic strategies in equity and credit markets. | 2012 | camcapital.com | New York, United States |
Investor details for AltruBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AltruBio
20 people are tracked at AltruBio (14 in leadership, 6 in board & advisors); the tracked headcount is 10.
| Name | Role | Group |
|---|---|---|
Ron Rh Lin | Founder | Leadership |
Judy Chou | CEO & President | Leadership |
Shih-Yao Lin | President of AltruBio Taiwan, Inc. & Head of Clinical Development, AltruBio, Inc. | Leadership |
Yu-Chi Hsieh | Director of Protein Science | Leadership |
Edwin Powers | Senior Director Business Development & Strategy | Leadership |
Ania Erdogan | Director, Human Resources | Leadership |
Simona Reed | VP of Clinical Operations | Leadership |
Leewen Lin | VP of Legal Affairs | Leadership |
Gene Lee | Chief Technical Officer | Leadership |
Jeroen Grasman | Chief Financial Officer | Leadership |
Zoe Chi | Associate Director of Project Managment | Leadership |
I-Ming Cho | Associate Director | Leadership |
Gene W. Lee, PhD | Chief Technical Officer | Leadership |
Mary Ann Gratol | Executive Assistant to Dr. Judy Chou, President & Chief Executive Officer | Leadership |
Patrick Y. Yang | Chairman of the Board | Board & advisors |
Stephen G. Juelsgaard | Director | Board & advisors |
David T. Rubin | Scientific Advisor | Board & advisors |
Sean P. Bohen | Director | Board & advisors |
Corsee D. Sanders | Director | Board & advisors |
John Doyle | Director | Board & advisors |
Complete people profiles for AltruBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AltruBio
2 dated milestones of AltruBio across 16 years, from founding to its latest funding, stage changes and deals.
- Funding First funding round of $6.2M.
- Funding Latest funding round, Series B, of $225.0M.
Web traffic of AltruBio
The website of AltruBio (altrubio.com) receives about 2.3K visits a month.
- Monthly visits2.3K
▲ 246% vs previous month
Websites whose visitors overlap most with AltruBio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| ligandal.com | 100% | – | – | View details | |
bplifescience.com | bplifescience.com | 99% | – | – | – |
| circlepharma.com | 98% | 2.8K | #6,088,315 | View details | |
| eurekatherapeutics.com | 97% | 1.7K | #7,320,910 | View details | |
| r2mpharma.com | 97% | 2.9K | #4,331,217 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 29 similar websites and full traffic analytics for AltruBio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 29 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
10 companies that operate in the same segment as AltruBio (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Altrubio
Complete news archive for AltruBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about AltruBio
AltruBio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Judy Chou is the current CEO of AltruBio.
AltruBio is a funded company, having raised a total of $339.6M across 7 funding rounds to date. The company's 1st funding round was a Series A of $6.15M, raised on Jul 2008.
AltruBio has 10 employees.
Developer of drugs for immune-mediated inflammation and cancer therapies. Its product AbGn-168H Neihulizumab is a humanized therapeutic antibody that induces apoptosis of late-stage activated T cells. This novel activated-T cell apoptosis-inducing antibody effectively eliminates chronic pathogenic T cells while fully maintaining host defense. It helps in the treatment of psoriatic arthritis, ulcerative colitis, and many more. The lead product AbGn-107 targets novel tumor-associated antigens on the surface of certain gastrointestinal cancers including the stomach, biliary system, pancreas, intestine, and rectum. The antibody can be internalized once it binds to cancer cells where the concentrated toxin efficiently kills the cancer cells. Other products include AbGn-268 Leiolizumab helps in treating inflammation diseases, AbGn-207 GI tumors.
AltruBio has 7 investors. Key investors include Blackstone, RA Capital, BVF Partners, Cormorant, and Soleus Capital.